MGCD-265 analog（Cat No.:I005271）is a multi-targeted kinase inhibitor designed to block key receptors such as MET, VEGFR, and AXL, which are involved in tumor growth, angiogenesis, and metastasis. By inhibiting these pathways, MGCD-265 analog disrupts cancer

MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.

InformationMGCD-265 is a potent, multi-target and ATP-competitive inhibitor ofc-MetandVEGFR1/2/3withIC50of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.In vitroMGCD-265 is a multi-target inhibitor of receptor tyrosine kinases. MGCD-265 potently inhibits

MGCD-265 is a potent, multi-target, and ATP-competitive receptor tyrosine kinase inhibitor of Met, Flt-1, Flt-4, Flk-1, Ron, and Tie-2 (IC50 = 1 nM - 7 nM).

Application：MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity

MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively and also inhibits Ron and Tie2.

Inhibits MET, VEGFR1-3, Tie and Ron tyrosine kinases; antineoplastic. Inhibits MET, VEGFR1-3, Tie and Ron tyrosine kinases; antineoplastic.

MGCD 265 is an orally bioavailable multi targeted tyrosine kinase inhibitor inhibiting MET VGFR1 3 Tie and Ron Formulations containing MGCD 265 alone or in combination with other chemotherapeutic compounds are being tested in animal